NCT07873294Completed
Letrozole Versus Letrozole and Inositol
Letrozole Versus Letrozole and Inositol in Ovulation Induction in PCO Patients
Source: ClinicalTrials.gov · Last updated 14 Oct 2026
Brief summary (registry, in English)
Polycystic ovary syndrome (PCOS) is one of the most common endocrine and metabolic disorders affecting women of reproductive age. Its prevalence varies considerably according to the population studied and the diagnostic criteria applied. A recent global systematic review and meta-analysis estimated the prevalence of PCOS among adult women to be approximately 12.1% according to the Rotterdam criteria, compared with 7.9% using the National Institutes of Health (NIH) criteria and 12.7% using the Androgen Excess-PCOS Society criteria.
- Status (registry)
- Completed
- Study type
- Interventional
- Enrollment
- 100 (actual)
- First submitted
- 18 Sept 2026
- Start date
- Aug 2025
- Primary completion date
- Aug 2026
- Lead sponsor
- Al-Azhar University
- NCT number
- NCT07873294
What you commit to
- Study type: Interventional
- Participants enrolled: 100
- From Aug 2025 to the primary completion date, Aug 2026
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Previous ovarian surgery.
- Use of ovulation-induction agents, insulin-sensitizing medications or other oral hypoglycemic agents, hormonal contraceptives, or anti-androgen medications within 60 days before enrollment.
Other illness
- Congenital adrenal hyperplasia or other adrenal disorders associated with androgen excess.
- Pituitary insufficiency.
- Known hypersensitivity or contraindication to letrozole or inositol.
Other
- Persistent hyperprolactinemia.
- Clinically significant thyroid dysfunction affecting ovulation.
Who the study is looking for
- Diagnosis of PCOS according to the Rotterdam criteria, requiring the presence of at least two of the following three features: oligo-ovulation or anovulation; clinical and/or biochemical hyperandrogenism; Polycystic ovarian morphology on ultrasonography.
- According to the prespecified study protocol, polycystic ovarian morphology was defined as the presence of ≥12 follicles measuring 2-9 mm in diameter and/or ovarian volume \>10 mL in at least one ovary.
- BMI \<30 kg/m².
- Documented anovulation, supported by a luteal serum progesterone concentration \<3 ng/mL.
- Bilateral tubal patency confirmed by hysterosalpingography.
- Absence of another identifiable female infertility factor.
- Normal semen analysis of the male partner.
Age in the registry: 18 years to 35 years · Sex: Female · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Al-Azhar University Hospital Assuit branch Coordinator of this site? Confirm its status | Asyut | Egypt | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.